QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.107.127167v1 323/1/119    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mandal, R. Articles by Kuppusamy, P. Search for Related Content PubMed PubMed Citation Articles by Mandal, R. Articles by Kuppusamy, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cardiomyopathy Hazardous Substances DB PYRROLE VERAPAMIL HYDROCHLORIDE

CARDIOVASCULAR

N-Hydroxy-pyrroline Modification of Verapamil Exhibits Antioxidant Protection of the Heart against Ischemia/Reperfusion-Induced Cardiac Dysfunction without Compromising Its Calcium Antagonistic Activity

Davis Heart and Lung Research Institute, Division of Cardiovascular Medicine, Department of Internal Medicine (R.M., V.K.K., M.K., I.K.M., S.V., P.K.) and College of Pharmacy (A.S., C.A.C.), Ohio State University, Columbus, Ohio; and Institute of Organic and Medicinal Chemistry, University of Pécs, Pécs, Hungary (T.K., K.H.)

Any clinical intervention (e.g., coronary angioplasty, thrombolysis) used to reintroduce blood flow to an ischemic region of the myocardium is accompanied by a complex enzymatic cascade of reactions resulting in severe injury to the heart, termed myocardial ischemia/reperfusion (I/R) injury. In this study, we evaluated the ability of H-3010 (1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrole-3-carboxylic acid (2-(3,4-dimethoxyphenyl)-5-([2-(3,4-dimethoxyphenyl)ethyl]-methylamino)-2-isopropylpentyl)-amide), a pyrroline modification of verapamil (2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethylmethyl-amino]-2-(1-methylethyl)pentanenitrile), to protect the heart against I/R-mediated injury. Isolated perfused rat hearts pretreated with verapamil and H-3010 were subjected to 30 min of global no-flow ischemia followed by 45 min of reperfusion. The recovery (expressed as a percentage of preischemic baseline) in contractile function (left ventricular developed pressure) of hearts subjected to I/R was significantly higher in hearts treated with H-3010 at 5 µM (51.0 ± 6.4%) as well as at 50 µM (75.1 ± 7.4%) as compared with verapamil at 5 µM (32.2 ± 3.7%) or untreated control hearts (18.1 ± 2.8%). Creatine kinase release was significantly attenuated in hearts treated with H-3010 (45.7 ± 4.5 U/liter) as compared with untreated controls (131.5 ± 6.4 U/liter). Similar trends were also observed for lactate dehydrogenase release as well. A marked reduction in percent area of infarction was observed in the H-3010 group (11.7 ± 1.6%) compared with verapamil (25.1 ± 2.9%) and control (41.3 ± 1.9%) groups. Additional in vitro studies showed a marked decrease in reactive oxygen species generation with H-3010. In conclusion, our data clearly demonstrated that the verapamil derivative, H-3010, significantly decreased I/R-induced cardiac dysfunction. This can be attributed to the combined benefits of the pyrroline moiety (antioxidant) and the parent verapamil component (antiarrhythmic) in the protection of the heart from I/R-induced injury.

Address correspondence to: Dr. Periannan Kuppusamy, Davis Heart and Lung Research Institute, Ohio State University, 420 West 12th Avenue, Room 114, Columbus, OH 43210. E-mail: kuppusamy.1{at}osu.edu

This article has been cited by other articles:

				I. K. Mohan, M. Khan, S. Wisel, K. Selvendiran, A. Sridhar, C. A. Carnes, B. Bognar, T. Kalai, K. Hideg, and P. Kuppusamy Cardioprotection by HO-4038, a novel verapamil derivative, targeted against ischemia and reperfusion-mediated acute myocardial infarction Am J Physiol Heart Circ Physiol, January 1, 2009; 296(1): H140 - H151. [Abstract] [Full Text] [PDF]